We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -32.25 | -4.15% | 744.50 | 778.08 | 754.29 | 778.08 | 3,258,550 | 01:00:00 |
From May 2019 to May 2024
By Matt Grossman
Eli Lilly and Co. has amended its purchase agreements with the U.S. government for two of the company's neutralizing-antibody therapies for Covid-19, the company said Monday.
Indianapolis-based Lilly said the changes were part of a transition to only supplying the two drugs, bamlanivimab and etesevimab, as a combination. As a result, the amended agreement cancels orders for the about 350,000 doses of bamlanivimab alone that Lilly was scheduled to deliver by the end of March.
In the future, Lilly said it plans to supply the U.S. government with additional doses of etesevimab to complement the doses of bamlanivimab that the government has already purchased.
Using the two drugs together to treat Covid-19 is a better way to address new variants of the underlying virus, SARS-CoV-2, Lilly said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
April 12, 2021 07:12 ET (11:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
